Simon Batzner

The best way to identify and work through the bottlenecks of drug development is to get deeply involved in real drug programs, across many different therapeutic areas and stages of development. Over the past several months, our scientists have engaged in deep research partnerships with six organizations developing new medicines: The Column Group, Generate Biomedicines, BigHat Biosciences, Divergence Labs, Enveda, and Bristol Myers Squibb. We’ve also begun our own drug discovery efforts through the acquisition of Mithril Medicine, a single-person biotech company co-founded by @atlasventure. Today we’re sharing early progress in accelerating drug discovery from these research collaborations. With Claude, we are streamlining operations and working to derisk novel targets with TCG, redesigning lab protocols with BigHat, designing CAR-T cell therapies with Generate, and multi-specific therapeutic antibodies with Divergence, drafting regulatory filings with Enveda, and supporting portfolio-level decision making with BMS. Our early collaborations span pre-clinical and clinical work on potential treatments for cancer, allergies, rare genetic diseases including forms of childhood muscular dystrophy, and more. My team has been working with @Prof_Oak_ , founder of Mithril Medicine, for the past year. Jason Rhodes, General Partner @atlasventure and Chairman of the Mithril Board said this about Mithril: “We prioritized LAMA2-Related Congenital Muscular Dystrophy (LAMA2-RD) as the lead indication, in part, because of the enormous unmet need. These patients present with the disease at birth, spend their lives in wheelchairs and on ventilators, and rarely live past their mid-twenties; yet no therapy is available, and few are in active development. We believed Mithril would be the company to change that.” Anthropic acquired Mithril and we are pushing the frontier of how a single skilled operator, with Claude, can run an entire pipeline of drugs. We’re working with these teams to show how AI can assist drug developers at many stages of the process already, and to prioritize improvements to our models based on the benchmarks we’re building with collaborators. Our blog includes links to technical reports written with our partners: anthropic.com/research/early…